Vivani Medical, Inc. financial data

Symbol
VANI on Nasdaq
Location
Alameda, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 187% % -56%
Debt-to-equity 269% % 149%
Return On Assets -79% % -62%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72,952,235 shares 23%
Common Stock, Shares, Outstanding 61,510,768 shares 11%
Entity Public Float $45,100,000 USD 16%
Weighted Average Number of Shares Outstanding, Basic 59,711,000 shares 8.1%
Weighted Average Number of Shares Outstanding, Diluted 59,711,000 shares 8.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $17,798,000 USD 10%
General and Administrative Expense $9,406,000 USD 14%
Operating Income (Loss) $27,204,000 USD -11%
Net Income (Loss) Attributable to Parent $26,026,000 USD -11%
Earnings Per Share, Basic 0 USD/shares 36%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,628,000 USD -87%
Assets, Current $4,175,000 USD -80%
Property, Plant and Equipment, Net $2,726,000 USD 66%
Operating Lease, Right-of-Use Asset $16,784,000 USD -8.7%
Other Assets, Noncurrent $1,338,000 USD 0%
Assets $25,046,000 USD -42%
Accounts Payable, Current $1,434,000 USD 76%
Employee-related Liabilities, Current $357,000 USD -3.8%
Accrued Liabilities, Current $1,978,000 USD -2.3%
Liabilities, Current $6,830,000 USD 8.9%
Operating Lease, Liability, Noncurrent $16,907,000 USD -7.6%
Liabilities $23,737,000 USD -3.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax $141,000 USD 53%
Retained Earnings (Accumulated Deficit) $141,900,000 USD -22%
Stockholders' Equity Attributable to Parent $1,309,000 USD -93%
Liabilities and Equity $25,046,000 USD -42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,163,000 USD -14%
Net Cash Provided by (Used in) Financing Activities $170,000 USD -101%
Net Cash Provided by (Used in) Investing Activities $5,000 USD 97%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 61,510,768 shares 11%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,344,000 USD -159%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19,690,000 USD -10%
Deferred Tax Assets, Valuation Allowance $69,581,000 USD 14%
Deferred Tax Assets, Gross $71,663,000 USD 14%
Operating Lease, Liability $18,294,000 USD -7%
Payments to Acquire Property, Plant, and Equipment $5,000 USD -97%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $25,977,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid $25,500,000 USD -10%
Property, Plant and Equipment, Gross $5,676,000 USD 36%
Operating Lease, Liability, Current $1,386,000 USD 0.07%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,976,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,889,000 USD -0.86%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7,206,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,065,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $198,668,000 USD 8.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,364,000 USD 40%
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,156,000 USD 3%
Operating Lease, Payments $30,019,000 USD
Additional Paid in Capital $143,062,000 USD 6.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $102,000 USD 3%
Share-based Payment Arrangement, Expense $1,419,000 USD -15%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%